Resimmune (A-dmDT390-bisFv(UCHT1))

About Angimmune

Angimmune is a private, pre-revenue biotech focused on a novel immunotoxin therapy, Resimmune (A-dmDT390-bisFv(UCHT1)), which targets the CD3 receptor on T-cells. Its lead indication is Cutaneous T-Cell Lymphoma (CTCL), where it has received FDA Fast Track and Orphan Drug designations. The company is exploring broader applications in autoimmune disorders, combination cancer immunotherapy, and a potentially transformative induction protocol to prevent antibody-mediated rejection in organ transplantation. With a short, four-day dosing regimen, the therapy offers a differentiated approach to modulating the immune system.

About Angimmune

Angimmune is a private, pre-revenue biotech focused on a novel immunotoxin therapy, Resimmune (A-dmDT390-bisFv(UCHT1)), which targets the CD3 receptor on T-cells. Its lead indication is Cutaneous T-Cell Lymphoma (CTCL), where it has received FDA Fast Track and Orphan Drug designations. The company is exploring broader applications in autoimmune disorders, combination cancer immunotherapy, and a potentially transformative induction protocol to prevent antibody-mediated rejection in organ transplantation. With a short, four-day dosing regimen, the therapy offers a differentiated approach to modulating the immune system.

About Angimmune

Angimmune is a private, pre-revenue biotech focused on a novel immunotoxin therapy, Resimmune (A-dmDT390-bisFv(UCHT1)), which targets the CD3 receptor on T-cells. Its lead indication is Cutaneous T-Cell Lymphoma (CTCL), where it has received FDA Fast Track and Orphan Drug designations. The company is exploring broader applications in autoimmune disorders, combination cancer immunotherapy, and a potentially transformative induction protocol to prevent antibody-mediated rejection in organ transplantation. With a short, four-day dosing regimen, the therapy offers a differentiated approach to modulating the immune system.

Therapeutic Areas